Smith, S. M., Schöder, H., Johnson, J. L., Jung, S., Bartlett, N. L., & Cheson, B. D. (2013). The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma.

Smith, Sonali M., Heiko Schöder, Jeffrey L. Johnson, Sin-Ho Jung, Nancy L. Bartlett, and Bruce D. Cheson. "The Anti-CD80 Primatized Monoclonal Antibody, Galiximab, Is Well-tolerated but Has Limited Activity in Relapsed Hodgkin Lymphoma: Cancer and Leukemia Group B 50602 (Alliance)." Leuk Lymphoma 2013.

Smith, Sonali M., et al. "The Anti-CD80 Primatized Monoclonal Antibody, Galiximab, Is Well-tolerated but Has Limited Activity in Relapsed Hodgkin Lymphoma: Cancer and Leukemia Group B 50602 (Alliance)." Leuk Lymphoma 2013.